Pmv Pharmaceuticals, Inc. (PMVP) intrinsic value & 10-year financials
Pmv Pharmaceuticals, Inc. (PMVP) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.21
- Market cap
- $63.6M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -23.5%
- Free cash flow (FY2025)
- -$73.6M
PMVP 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$77.7M | -$1.48 | -$73.6M | — | -82.5% |
| FY2024 | — | -$58.7M | -$1.14 | -$51.9M | — | -39.9% |
| FY2023 | — | -$69.0M | -$1.44 | -$56.6M | — | -45.6% |
| FY2022 | — | -$73.3M | -$1.61 | -$71.7M | — | -51.7% |
| FY2021 | — | -$57.8M | -$1.28 | -$47.9M | — | -39.7% |
| FY2020 | — | -$34.4M | -$0.80 | -$32.9M | — | -24.2% |
| FY2019 | — | -$25.4M | — | -$22.2M | — | 45.7% |
| FY2018 | — | -$17.5M | — | -$15.6M | — | 49.8% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
PMV Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
PMV Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just -23.5% ROIC.
PMV Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
PMV Pharmaceuticals, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.